This study may not only impact the development of novel DOT1L inhibitors, but also reveal key characteristics of KMT2A-rearranged ALL cells that are able to evade therapy, providing therapeutic targets to prevent that. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.